Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors

References

• Fraenkel M, Kim M, Faggiano A, Herder WW, Valk GD. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr. Relat. Cancer 21(3), 153–163 (2014).
   PubMed Web of Science ®Google Scholar
• Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121(4), 589–597 (2015).
   PubMed Web of Science ®Google Scholar
• Young K, Iyer R, Morganstein D, Chau I, Cunningham D, Starling N. Pancreatic neuroendocrine tumors: a review. Future Oncol. 11(5), 853–864 (2015).
   PubMed Web of Science ®Google Scholar
• Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J. Clin. Oncol. 33(16), 1855–1863 (2015).
   PubMed Web of Science ®Google Scholar
• Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract. Res. Clin. Gastroenterol. 26(6), 737–753 (2012).
   PubMed Web of Science ®Google Scholar
• Kulke MH, Shah MH, Benson AB 3rd et al. Neuroendocrine tumors, version 1.2015. J. Natl Compr. Canc. Netw. 13(1), 78–108 (2015).
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Ćwikła JB et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 371(3), 224–233 (2014).
   PubMed Web of Science ®Google Scholar
• Rossi RE, Massironi S, Conte D, Peracchi M. Therapy for metastatic pancreatic neuroendocrine tumors. Ann. Transl. Med. 2(1), 8 (2014).
   PubMedGoogle Scholar
• Clift AK, Frilling A. Management of patients with hepatic metastases from neuroendocrine tumors. Ann. Saudi Med. 34(4), 279–290 (2014).
   PubMed Web of Science ®Google Scholar
• Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer 121(8), 1172–1186 (2015).
   PubMed Web of Science ®Google Scholar
• Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-liver-metastases consensus conference. HPB (Oxford) 17(1), 29–37 (2015).
   PubMed Web of Science ®Google Scholar
• Del Prete M, Fiore F, Modica R et al. Hepatic arterial embolization in patients with neuroendocrine tumors. J. Exp. Clin. Cancer Res. 33, 43 (2014).
   PubMed Web of Science ®Google Scholar
• Bernard V, Lombard-Bohas C, Taquet MC et al. Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. Eur. J. Endocrinol. 168(5), 665–674 (2013).
   PubMed Web of Science ®Google Scholar
• Igarashi H, Hijioka M, Lee L, Ito T. Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs. J. Hepatobiliary Pancreat. Sci. 22, 618–622 (2015).
   PubMed Web of Science ®Google Scholar
• Paprottka PM, Hoffman RT, Haug A et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc. Intervent. Radiol. 35(2), 334–342 (2012).
   PubMed Web of Science ®Google Scholar
• Devcic Z, Rosenberg J, Braat AJ et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J. Nucl. Med. 55(9), 1404–1410 (2014).
   PubMed Web of Science ®Google Scholar
• Raj N, Reidy-Lagunes D. Systemic therapies for advanced pancreatic neuroendocrine tumors. Hematol. Oncol. Clin. North Am. 30(1), 119–133 (2016).
   PubMed Web of Science ®Google Scholar
• Verbeek, WH M, Korse CM, Tesselaar ME. Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers. Eur. J. Endocrinol. 174(1), R1–R7 (2016).
   PubMed Web of Science ®Google Scholar
• Wolin EM, Malon A, Chassaing C et al. Lanreotide depot: an antineoplastic treatment of carcinoid or neuroendocrine tumors. J. Gastrointest. Cancer 47(4), 366–374 (2016).
   PubMedGoogle Scholar
• Orlewska E, Bednarczuk T, Kaminski G, Kos-Kudla B. LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in polish patients with neuroendocrine tumors: results of interim analysis. Contemp. Oncol. 18(6), 442–447 (2014).
   Google Scholar
• Paragliola RM, Prete A, Papi G et al. Clinical utility of lanreotide autogel® in gastroenteropancreatic neuroendocrine tumors. Drug Des. Devel. Ther. 10, 3459–3470 (2016).
   PubMed Web of Science ®Google Scholar
• Grandhi MS, Lafaro KJ, Pawlik TM. Role of locoregional and systemic approaches for the treatment of patients with metastatic neuroendocrine tumors. J. Gastrointest. Surg. 19(12), 2273–2282 (2015).
   PubMed Web of Science ®Google Scholar
• Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br. J. Radiol. 89(1062), 20150943, (2016).
   PubMed Web of Science ®Google Scholar
• Kuei A, Saab S, Cho SK, Kee ST, Lee EW. Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. World J. Gastroenterol. 21(27), 8271–8283 (2015).
   PubMed Web of Science ®Google Scholar
• Padia SA, Lewandowski RJ, Johnson GE et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J. Vasc. Interv. Radiol. 28(1), 1–15 (2017).
   PubMed Web of Science ®Google Scholar
• Cives M, Strosberg J. Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract. Curr. Treat. Options Oncol. 18(3), 14 (2017).
   PubMed Web of Science ®Google Scholar
• Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndrome. Expert. Opin. Pharmacother. 17(16), 2192–2205 (2016).
   Web of Science ®Google Scholar
• King J, Quinn R, Glenn DM et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113(5), 921–929 (2008).
   PubMed Web of Science ®Google Scholar
• Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. Am. J. Clin. Oncol. 35(1), 393–398 (2012).
   PubMedGoogle Scholar
• Pavel M, O´Toole D, Costa F et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2), 172–185 (2016).
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman OM, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst. 2, 11–15 (2016).
   Google Scholar
• De Baere T, Deschamps F, Tselikas L et al. GEP-NETs update: interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur. J. Endocrinol. 172(4), R151–R166 (2015).
   PubMed Web of Science ®Google Scholar
• Oronsky B, Ma PC, Morgensztern D et al. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia 19(12), 991–1002 (2017).
   PubMed Web of Science ®Google Scholar
• Ezziddin S, Meyer C, Kahancova S et al. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J. Nucl. Med. 53(11), 1663–1669 (2012).
   PubMed Web of Science ®Google Scholar
• Flippi L, Ciorra A, Sardella B et al. Sequential use of (90)Y microspheres radioembolization and (177)Lu-dotatate in pluri-metastatic neuroendocrine tumors: a case report. Nucl. Med. Mol. Imaging 48(4), 321–325 (2014).
   PubMedGoogle Scholar